SenzaGen H2: Initial take on H2 2023 results – a solid half-year - Redeye

Redeye provides an initial take on SenzaGen’s H2 2023 report. The sales for the second half of 2023 came in at SEK26.3m, in line with our sales estimate of SEK26.5m. Moreover, EBIT came in at SEK-10.0m, slightly better than our estimate of SEK-12.1m. We argue the report is solid and will provide an update shortly where we expect to make some estimate changes; however, we do not expect our fair value range to be impacted significantly.

Länk till analysen i sin helhet: https://www.redeye.se/research/978982/senzagen-h2-initial-take-on-h2-2023-results-a-solid-half-year?utm_source=finwire&utm_medium=RSS